California State Teachers Retirement System Raises Stake in Vaxcyte, Inc. (NASDAQ:PCVX)

California State Teachers Retirement System grew its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 17.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 105,052 shares of the company's stock after acquiring an additional 15,616 shares during the quarter. California State Teachers Retirement System owned about 0.08% of Vaxcyte worth $8,600,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Blue Trust Inc. boosted its position in Vaxcyte by 125.1% during the 4th quarter. Blue Trust Inc. now owns 835 shares of the company's stock valued at $68,000 after acquiring an additional 464 shares in the last quarter. KBC Group NV grew its stake in shares of Vaxcyte by 78.0% in the fourth quarter. KBC Group NV now owns 4,775 shares of the company's stock valued at $391,000 after buying an additional 2,092 shares in the last quarter. Chicago Partners Investment Group LLC grew its position in shares of Vaxcyte by 9.2% during the fourth quarter. Chicago Partners Investment Group LLC now owns 5,431 shares of the company's stock worth $440,000 after buying an additional 458 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Vaxcyte by 23.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 26,428 shares of the company's stock valued at $2,163,000 after purchasing an additional 4,962 shares during the last quarter. Finally, Jennison Associates LLC grew its position in shares of Vaxcyte by 0.7% during the fourth quarter. Jennison Associates LLC now owns 1,246,551 shares of the company's stock worth $102,043,000 after acquiring an additional 9,121 shares during the last quarter. 96.78% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. The Goldman Sachs Group cut their price objective on Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Needham & Company LLC reaffirmed a "buy" rating and set a $90.00 target price on shares of Vaxcyte in a report on Tuesday, April 8th. Guggenheim reaffirmed a "buy" rating and issued a $160.00 price objective on shares of Vaxcyte in a research note on Wednesday, March 12th. Cantor Fitzgerald initiated coverage on Vaxcyte in a report on Tuesday, April 22nd. They issued an "overweight" rating for the company. Finally, Bank of America dropped their target price on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $136.50.

Vaxcyte Stock Performance

NASDAQ PCVX traded down $0.81 during trading on Wednesday, hitting $33.84. The stock had a trading volume of 1,201,943 shares, compared to its average volume of 1,419,296. The stock has a market capitalization of $4.37 billion, a price-to-earnings ratio of -7.36 and a beta of 1.20. Vaxcyte, Inc. has a one year low of $27.66 and a one year high of $121.06. The stock has a 50 day simple moving average of $32.22 and a 200 day simple moving average of $65.79.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). During the same period in the prior year, the business posted ($0.85) EPS. On average, sell-side analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.